The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

December 31, 2010

Conditions
Liver Failure
Interventions
DRUG

entecavir

Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.

DRUG

Traditional comprehensive medical treatment

bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.

Trial Locations (1)

510630

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT01254994 - The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure | Biotech Hunter | Biotech Hunter